Not Verified

PREVENT Cancer Preclinical Drug Development Program

National Cancer Institute

The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. PREVENT allocates NCI contract resources and expertise to generate data and materials, which are used by the applicants for further development. PREVENT's current research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers. For more information, visit DCP PREVENT.

Apply to PREVENT

1Submit an Application

You may submit more than one application per application cycle. All applications must be submitted through this website. Please see application instructions for specifics on creating the concept application which will be uploaded to the application.

NCI will accept only a single resubmission to the PREVENT Program. The resubmission should include responses to the comments and recommendations from the scientific reviews and explain how the application has been modified and strengthened.

Begin an application

Applications must be submitted by Nov. 2, 2026, 11:59 p.m.

2Wait for Application Review

Applications are reviewed by the Scientific Review Panel and the Management and Administrative Committee.

The Scientific Review Panel is made of up extramural scientists who are experts in molecular biology, chemoprevention, animal efficacy testing, medicinal chemistry, immunology, toxicology, pharmacology, drug development, and ad hoc members as needed. This panel reviews, scores, and ranks applications.

The Management and Administrative Committee is made up of Senior DCP staff, Division Leadership, staff from the NCI's divisions and NIH ICs.

3Receive Final Decision

You will be notified of the final decision on applications you have submitted within approximately 4 months.

AI Based Application Success Predictor

Category	Details
Organization	National Cancer Institute (NCI)
Organization type	U.S. federal government agency; part of the National Institutes of Health (NIH).
Primary research areas	Cancer biology, prevention, diagnosis, treatment, cancer control, survivorship, and translational research.
Previous success predictors	1. Scientific significance and potential impact on cancer research. 2. Innovation and novelty. 3. Rigor and feasibility of the research methodology. 4. Investigator expertise and relevant research experience. 5. Institutional resources and research environment. 6. Alignment with NCI priorities and unmet cancer research needs. 7. Strong preliminary evidence, where appropriate. 8. Appropriate study design and statistical analysis. 9. Realistic budget and timeline. 10. Compliance with eligibility and application requirements.
Additional funding decision factors	Public health significance, investigator career stage, existing NCI funding, representation of the research topic within the NCI portfolio, and availability of funds. Grants & Funding
Historical success rate	Not established here; success rates vary by funding mechanism, fiscal year, and applicant category.

Excel-ready entry

Previous Success Predictors: Scientific significance; research innovation; methodological rigor and feasibility; investigator expertise; institutional resources; cancer research priority alignment; preliminary data; appropriate study design and statistical analysis; realistic budget; investigator career stage; existing funding; public health impact; and availability of funds.

Grants & Funding

Important: For most NIH research project grants with application due dates on or after January 25, 2025, peer review uses a simplified framework covering research importance, rigor and feasibility, and investigator expertise and resources. NCI also considers portfolio priorities and funding availability when making funding decisions.

Specialties

Cancer

Oncology

Drug Development

Pharmacology

Eligibility Requirements

The Management and Administrative Committee is made up of Senior DCP staff, Division Leadership, staff from the NCI's divisions and NIH ICs.

Eligible Countries:

United States

Sponsor Details

Sponsor Institute/Organizations: National Cancer Institute

Sponsor Type: Corporate/Non-Profit

Address: 9609 Medical Center Drive, Rockville, MD 20850

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity